Sex hormones, lipoproteins, and vascular reactivity

Current Opinion in Lipidology

Volumn 6, Issue 3, 1995, Pages 161-166

  Sacks, Frank M ^a,d   Gerhard, Marie ^b,c   Walsh, Brian W ^c  

^a CHANNING LABORATORY   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; ESTRADIOL; ESTROGEN; ETHINYLESTRADIOL; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN; LIPOPROTEIN A; MEDROXYPROGESTERONE ACETATE; SEX HORMONE; TESTOSTERONE;

ANTIOXIDANT ACTIVITY; ARTERY DILATATION; ATHEROSCLEROSIS; BLOOD VESSEL REACTIVITY; CARDIOVASCULAR FUNCTION; CLINICAL TRIAL; CORONARY ARTERY; DRUG EFFECT; ESTROGEN THERAPY; FOREARM; HEMODYNAMICS; HORMONE ACTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIPOPROTEIN METABOLISM; MENSTRUAL CYCLE; NONHUMAN; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; PRIORITY JOURNAL; RESISTANCE BLOOD VESSEL; REVIEW; RISK FACTOR; TRANSDERMAL DRUG ADMINISTRATION; VASCULAR ENDOTHELIUM;

EID: 0029059943     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-199506000-00008     Document Type: Review

References (40)

1. Sacks FM, Walsh BW: Sex hormones and lipoprotein metabolism. Curr Opin Lipidol 1994, 5:236-240. An extensive review of the effects of estrogen and progestins on VLDL and LDL metabolism.
2. Walsh BW, Schiff I. Rosner B, Breenberg L, Ravnikar V, Sacks FM Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med 1991, 325:1196-1204.
3. 2 and hepatic lipase: reciprocal changes produced by estrogen and norgestrel. J Clin Endocrinol Metab 1982, 54:1113-1117.
4. Schaefer EJ, Foster DM, Zech LA, Lindgren FT, Brewer HB, Levy RI: The effects of estrogen administration on plasma lipoprotein metabolism in premenopausal females. J Clin Endocrinol Metab 1983, 57:262-267.
5. Srivastava RAK, Baumann D, Schonfeld G: In-vivo regulation of LDL receptors by estrogen differs at the post-transcriptional level in rat and mouse, Eur J Biochem 1993, 216:527-538.
6. 3-apoA-I by 11%, whereas transdermal estradiol had no significant effect. These increased apoA-I levels resulted entirely from increased production because their fractional catabolic rates were unchanged.
7. Matthews KA, Meilahn E, Kuller LH, Kelsey SF, Caggiula AW, Wing RR: Menopause and risk factors for coronary artery disease. N Engl J Med 1989, 321:1311-1316.
8. 2b subfraction. The authors attributed the HDL increase to higher estrogen levels.
9. Lyons Wall PM, Choudhury N, Gerbrandy EA, Truswell AS: Increase of HDL cholesterol at ovulation in healthy women. Atherosclerosis 1994, 105:1171-1178. The HDL levels in 12 healthy premenopausal women were significantly lower (by 10%) during the premenstrual phase compared with the rest of the cycle. This fall in HDL levels could have been caused by the premenstrual decline in estradiol levels or, alternatively, by the appearance of progesterone in the luteal phase, or a combination of both.
10. Kim CJ, Jang HC, Cho DH, Min YK: Effects of hormone replacement therapy on lipoprotein (a) and lipids in postmenopausal women. Arterioscler Thromb 1994, 14:275-281.
11. Miller VT, Muesing RA, LaRosa JC, Stoy DB, Fowler SE, Stillman RJ: Quantitative and qualitative changes in lipids, lipoproteins, apolipoprotein A-I, and sex hormone-binding globulin due to two doses of conjugated equine estrogen with and without a progestin. Obstet Gynecol 1994, 83:173-179. The authors studied 102 postmenopausal women assigned to one of two doses of CEE for 4 months, followed by the same estrogen dose and the progestin, MPA. The estrogen-induced increase in HDL was completely reversed by the progestin.
12. Lobo RA, Pickar JH, Wild RA, Walsh BW, Hirvonen E: Metabolic impact of adding medroxyprogesterone acetate to conjugated estrogen therapy in postmenopausal women. Obstet Gynecol 1994, 84:987-995. A group of 525 healthy postmenopausal women were randomized to receive one of five treatments for 1 year [CEE (0.625 mg) alone, CEE with MPA (2.5 or 5.0mg) given daily or CEE with MPA (5 or 10mg) given cyclically]. All regimens of MPA nearly completely reversed the HDL increase produced by estrogen alone. Lp(a), LDL, and triglycerides were not affected by MPA.
13. The writing group for the PEPI trial: Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA 1995, 273:199-208. A group of 875 healthy postmenopausal women were randomized to receive one of five treatments for 3years [placebo, CEE (0.625 mg), CEE and cyclic MPA (10 mg), CEE and MPA (2.5 mg/day), CEE and cyclic micronized progesterone (2.0mg)S. MPA lowered HDL and eliminated approximately two-thirds of the HDL-raising effect of estrogen, whereas micronized progesterone had no significant effect. Progestins did not alter the LDL-lowering or triglyceride-raising effects of estrogen.
14. Bagatell CJ, Knopp RH, Vale WW, Rivier JE, Bremner WJ: Physiologic testosterone levels in normal men suppress HDL cholesterol levels. Ann Intern Med 1992, 116:967-973.
15. Bagatell CJ, Heiman JR, Matsumoto AM, Rivier JE, Bremner WJ: Metabolic and behavioral effects of high-dose, exogenous testosterone in healthy men. J Clin Endocrinol Metab 1994, 79:561-567.
16. 1 cholesterol. Metabolism 1994, 43:935-939. Testosterone lowered HDL by 15% in two hypoandrogenic groups: 8 hypogonadal men and 10 women (preoperative female-to-male transsexuals), whereas LDL and triglyceride levels were unaffected. Although both groups were hypogonadic, the pretreatment HDL levels were higher in women compared with the men, which suggests that the combination of estrogenic and androgenic influences is responsible for the sex difference in HDL levels.
17. 2 cholesterol levels in normal men. J Clin Endocrinol Metab 1994, 78.855-861.
18. Sacks FM, McPherson R, Walsh BW: Effect of postmenopausal estrogen replacement on plasma Lp(a) lipoprotein concentrations. Arch Intern Med 1994, 154:1106-1110. Two doses of conjugated estrogens (0.625 mg/day and 1-25 mg/day) lowered Lp(a) levels by 14 and 16%, respectively in 31 postmenopausal women in a randomized, placebo-controlled, doubie-blind trial.
19. Gisclard V, Miller VM, Vanhoutte PM: Effect of 17-beta estradiol on endothelium-dependent responses in the rabbit. J Pharmacol Exp Ther 1988, 244:19-22.
20. Miller VM, Vanhoutte PM: Progesterone and modulation of endothelium-dependent responses in canine coronary arteries. Am J Physiol 1991, 261:R1022-R1027.
21. Vita JA, Treasure CB, Nabel EG, McLenachan JM, Fish RD, Yueng AC, Vekshtein VI, Selwyn AP, Ganz P: Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation 1990, 81:491-497.
22. Creager MA, Cooke JP, Mendelsohn ME, Gallagher SJ, Coleman SM, Loscalzo J, Dzau VJ: Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans. J Clin Invest 1990, 86.228-234.
23. Panza JA, Quyyumi AA, Brush JE, Epstein SE: Abnormal endotnelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med 1990, 323-22-27.
24. Johnstone MT, Creager SJ, Scales KM, Cusco JA, Lee BK, Creager MA: Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. Circulation 1993, 88:2510-2516.
25. Hayashi T, Fukoto JM, Ignarro LJ, Chaudhuri G: Basal release of nitric oxide from aortic rings is greater in female rabbits than in male rabbits: implications for atherosclerosis. Proc Natl Acad Sci USA 1992, 89:11259-11263.
26. Miller VM, Gisclard V, Vanhoutte PM: Modulation of endothelium-dependent and vascular smooth muscle responses by oestrogens. Phlebology 1988, 3:63-69.
27. Chang WC, Nakao J, Orimo H, Murota SI: Stimulation of prostacyclin activity in rat aorta smooth muscle cell in culture. Biochim Biophys Acta 1980, 619:107-118.
28. Jiang C, Sarrel PM, Poole-Wilson PA, Collins P: Acute effect of 17-beta estradiol on rabbit coronary artery contractile responses to endothelin-1. Am J Physiol 1992, 263:271-275.
29. Williams JK, Adams MR, Klopfstein HS: Estrogen modulates responses of atherosclerotic coronary arteries. Circulation 1990, 81:1680-1687.
30. William SP, Shackelford DP, lams SH, Mustafa SJ: Endothelium-dependent relaxation in spontaneously hypertensive rats, Eur J Pharmacol 1988, 81:1752-1758.
31. Williams JK, Kim YD, Adams MR, Chen MF, Myers AK, Ramwell PW: Effects of estrogen on cardiovascular responses of premenopausal monkeys. J Pharmacol Exp Ther 1994 271:671-675. Premenopausal monkeys were treated for 6 weeks with a placebo, lowdose or high-dose estrogen. High-dose but not low-dose estrogen produced hemodynamic changes, including an increased cardiac index and decreased systemic vascular resistance.
32. Reis SE, Cloth ST, Blumenthal RS, Resar JR, Zacur HA, Gerstenblith G, Brinker JA: Ethinyl estradiol acutely attenuates abnormal coronary vasomotor responses to acetylcholine in postmenopausal women. Circulation 1994, 89:52-60. Intravenous ethinyl estradiol increased coronary flow and decreased resistance in postmenopausal women undergoing cardiac cathetenzation Estradiol improved abnormal endothelium-dependent vascular responses.
33. Gilligan DM, Quyyumi AA, Cannon RO: Effects of physiological levels of estrogen on coronary vasomotor function in postmenopausal women. Circulation 1994, 89:2545-2551. The intracoronary infusion of estradiol improved endothelium-dependent vasodilation but the endothellum-independent vascular responses were not affected in postmenopausal women.
34. Gilligan DM, Badar DM, Panza JA, Quyyumi AA, Cannon RO: Acute vascular effects of estrogen in postmenopausal women. Circulation 1994, 90:786-791. Physiological levels of estradiol potentiated endothelium-dependent vasodilation in forearm resistance vessels of healthy postmenopausal women. In patients with risk factors for atherosclerosis, estrogen also improved the endothelium-mdependent responses.
35. Keaney JF, Shaery GT, Xu A, Nicolosi RJ, Loscalzo J, Foxall TL, Vita JA: 17-Beta estradiol preserves endothelial vasodilator function and limits low-density lipoprotein oxidation in hypercholesterolemic swine. Circulation 1994, 89:2251-2259. Increased levels of antioxidants can decrease the degradation of endothelium-derived relaxing factor and protect blood vessels from oxidative damage that contributes to endothelial dysfunction. In hypercholesterolemic swine with and without ovariectomy, estradiol replacement therapy protected LDL-cholesterol against oxidative modification and improved the impaired coronary artery endothelium-dependent vasomotor responses.
36. Sack MN, Rader DJ, Cannon RO: Oestrogen and inhibition of oxidation of LDL in postmenopausal women, lancet 1994, 343:269-270. In postmenopausal women, estrogen replacement inhibited in-vitro LDL oxidation.
37. Collins P, Shay J, Jiang C, Moss J: Nitric oxide accounts for dose-dependent estrogen-mediated coronary relaxation after acute estrogen withdrawal. Circulation 1994, 90:1964-1968.
38. Lieberman EH, Gerhard MD, Uehata A, Walsh BW, Selwyn AP, Ganz P, Yeung AC, Creager MA: Estrogen improves flow-mediated vasodilation in postmenopausal women. Ann Intern Med 1994, 121:936-941. Healthy postmenopausal women were treated with oral, micronized estradiol (1 mg/day or 2mg/day) in a double-blind, placebo-controlled, crossover trial that examined two doses of estradiol replacement. Estrogen improved flow-mediated, endothelium-dependent vasodilation in the forearm.
39. Karas RH, Patterson BL, Mendelsohn ME: Human vascu-lar smooth muscle cells contain function estrogen receptor. Circulation 1994, 89:1943-1950.
40. Losordo DW, Kearney M, Kim EA, Jekanowski J, Isner JM: Variable expression of the estrogen receptor in normal and atherosclerotic coronary arteries of premenopausal women. Circulation 1994, 89:1501-1510.